Tyra Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
TYRA$22.30+5.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · AccumulatedDeficit · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2023 | 43,024,634 | $4 | $368,707 | $381 | $(164,830) | $204,262 |
| Issuance of common stock under Private Placement, net of issuance costs of $0.2 million | 9,286,023 | 1 | 120,557 | — | — | 120,558 |
| Issuance of pre-funded warrants, net of issuance costs of $0.2 million | — | — | 79,022 | — | — | 79,022 |
| Issuance of common stock pursuant to pre-funded warrant exercise | 705,000 | — | — | — | — | — |
| Exchange of common stock for pre-funded warrants | (3,000,000) | — | — | — | — | — |
| Issuance of common stock under benefit plans | 664,184 | — | 2,557 | — | — | 2,557 |
| Vesting of shares of common stock subject to repurchase | 70,104 | — | 43 | — | — | 43 |
| Stock-based compensation | — | — | 22,801 | — | — | 22,801 |
| Unrealized gain on marketable securities available-for-sale, net | — | — | — | 389 | — | 389 |
| Net loss | — | — | — | — | (86,481) | (86,481) |
| Balance at December 31, 2024 | 50,749,945 | $5 | $593,687 | $770 | $(251,311) | $343,151 |
| Issuance of common stock pursuant to pre-funded warrant exercise | 2,000,069 | — | — | — | — | — |
| Issuance of common stock under benefit plans | 952,026 | — | 8,341 | — | — | 8,341 |
| Vesting of shares of common stock subject to repurchase | 4,317 | — | 3 | — | — | 3 |
| Stock-based compensation | — | — | 28,006 | — | — | 28,006 |
| Unrealized loss on marketable securities available-for-sale, net | — | — | — | (377) | — | (377) |
| Net loss | — | — | — | — | (119,947) | (119,947) |
| Balance at December 31, 2025 | 53,706,357 | $5 | $630,037 | $393 | $(371,258) | $259,177 |
State
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.